Follicular dendritic cell sarcoma

A report of 14 cases and a review of the literature

Andres O. Soriano, Michael A. Thompson, Joan Admirand, Luis E. Fayad, Alma M. Rodriguez, Jorge E. Romaguera, Fredrick B. Hagemeister, Barbara Pro

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Follicular dendritic cell sarcomas (FDCS) are grouped with the histiocytic and dendritic cell neoplasms. The natural history and response to different treatments have not been well established. The cases of 14 patients with FDCS who were seen at M. D. Anderson between 1995 and 2005 were reviewed. Median patient age was 48 years (range, 25-69 years). Histologically, four cases showed low-grade features, three cases showed low-grade features with focal high-grade features, and five cases showed high-grade features. Tumors were positive for CD21, CD23, and CD35 in 83, 90, and 44% of cases, respectively. Twelve (92%) of 13 tumors were strongly positive for epidermal growth factor receptor. Information on initial treatment was available in 11 patients, which included surgery alone in one patient, surgery and radiation in two, surgery and chemotherapy in one, chemotherapy alone in three, chemotherapy and radiation in one, surgery followed by radiation and chemotherapy in three patients. In eight patients the initial chemotherapy regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone. Complete remission was achieved in 7 (63%) of 11 patients. Ten patients were alive at a median follow up of 22 months, 3 (23%) of 13 had no evidence of disease, and 7 (53%) of 13 patients were alive with disease. Follicular sarcoma is an aggressive neoplasm. Although most of the patients initially responded to treatment, the majority of them (81%) relapsed. A better understanding of the biology of FDCS could guide our efforts in the development of new treatment modalities for this rare disease.

Original languageEnglish (US)
Pages (from-to)725-728
Number of pages4
JournalAmerican journal of hematology
Volume82
Issue number8
DOIs
StatePublished - Aug 1 2007

Fingerprint

Follicular Dendritic Cell Sarcoma
Drug Therapy
Radiation
Neoplasms
Vincristine
Therapeutics
Rare Diseases
Prednisone
Natural History
Epidermal Growth Factor Receptor
Sarcoma
Doxorubicin
Cyclophosphamide
Dendritic Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Soriano, A. O., Thompson, M. A., Admirand, J., Fayad, L. E., Rodriguez, A. M., Romaguera, J. E., ... Pro, B. (2007). Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature. American journal of hematology, 82(8), 725-728. https://doi.org/10.1002/ajh.20852

Follicular dendritic cell sarcoma : A report of 14 cases and a review of the literature. / Soriano, Andres O.; Thompson, Michael A.; Admirand, Joan; Fayad, Luis E.; Rodriguez, Alma M.; Romaguera, Jorge E.; Hagemeister, Fredrick B.; Pro, Barbara.

In: American journal of hematology, Vol. 82, No. 8, 01.08.2007, p. 725-728.

Research output: Contribution to journalArticle

Soriano, AO, Thompson, MA, Admirand, J, Fayad, LE, Rodriguez, AM, Romaguera, JE, Hagemeister, FB & Pro, B 2007, 'Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature', American journal of hematology, vol. 82, no. 8, pp. 725-728. https://doi.org/10.1002/ajh.20852
Soriano, Andres O. ; Thompson, Michael A. ; Admirand, Joan ; Fayad, Luis E. ; Rodriguez, Alma M. ; Romaguera, Jorge E. ; Hagemeister, Fredrick B. ; Pro, Barbara. / Follicular dendritic cell sarcoma : A report of 14 cases and a review of the literature. In: American journal of hematology. 2007 ; Vol. 82, No. 8. pp. 725-728.
@article{a7dfbaf74be54c838435c7797d6653b6,
title = "Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature",
abstract = "Follicular dendritic cell sarcomas (FDCS) are grouped with the histiocytic and dendritic cell neoplasms. The natural history and response to different treatments have not been well established. The cases of 14 patients with FDCS who were seen at M. D. Anderson between 1995 and 2005 were reviewed. Median patient age was 48 years (range, 25-69 years). Histologically, four cases showed low-grade features, three cases showed low-grade features with focal high-grade features, and five cases showed high-grade features. Tumors were positive for CD21, CD23, and CD35 in 83, 90, and 44{\%} of cases, respectively. Twelve (92{\%}) of 13 tumors were strongly positive for epidermal growth factor receptor. Information on initial treatment was available in 11 patients, which included surgery alone in one patient, surgery and radiation in two, surgery and chemotherapy in one, chemotherapy alone in three, chemotherapy and radiation in one, surgery followed by radiation and chemotherapy in three patients. In eight patients the initial chemotherapy regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone. Complete remission was achieved in 7 (63{\%}) of 11 patients. Ten patients were alive at a median follow up of 22 months, 3 (23{\%}) of 13 had no evidence of disease, and 7 (53{\%}) of 13 patients were alive with disease. Follicular sarcoma is an aggressive neoplasm. Although most of the patients initially responded to treatment, the majority of them (81{\%}) relapsed. A better understanding of the biology of FDCS could guide our efforts in the development of new treatment modalities for this rare disease.",
author = "Soriano, {Andres O.} and Thompson, {Michael A.} and Joan Admirand and Fayad, {Luis E.} and Rodriguez, {Alma M.} and Romaguera, {Jorge E.} and Hagemeister, {Fredrick B.} and Barbara Pro",
year = "2007",
month = "8",
day = "1",
doi = "10.1002/ajh.20852",
language = "English (US)",
volume = "82",
pages = "725--728",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Follicular dendritic cell sarcoma

T2 - A report of 14 cases and a review of the literature

AU - Soriano, Andres O.

AU - Thompson, Michael A.

AU - Admirand, Joan

AU - Fayad, Luis E.

AU - Rodriguez, Alma M.

AU - Romaguera, Jorge E.

AU - Hagemeister, Fredrick B.

AU - Pro, Barbara

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Follicular dendritic cell sarcomas (FDCS) are grouped with the histiocytic and dendritic cell neoplasms. The natural history and response to different treatments have not been well established. The cases of 14 patients with FDCS who were seen at M. D. Anderson between 1995 and 2005 were reviewed. Median patient age was 48 years (range, 25-69 years). Histologically, four cases showed low-grade features, three cases showed low-grade features with focal high-grade features, and five cases showed high-grade features. Tumors were positive for CD21, CD23, and CD35 in 83, 90, and 44% of cases, respectively. Twelve (92%) of 13 tumors were strongly positive for epidermal growth factor receptor. Information on initial treatment was available in 11 patients, which included surgery alone in one patient, surgery and radiation in two, surgery and chemotherapy in one, chemotherapy alone in three, chemotherapy and radiation in one, surgery followed by radiation and chemotherapy in three patients. In eight patients the initial chemotherapy regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone. Complete remission was achieved in 7 (63%) of 11 patients. Ten patients were alive at a median follow up of 22 months, 3 (23%) of 13 had no evidence of disease, and 7 (53%) of 13 patients were alive with disease. Follicular sarcoma is an aggressive neoplasm. Although most of the patients initially responded to treatment, the majority of them (81%) relapsed. A better understanding of the biology of FDCS could guide our efforts in the development of new treatment modalities for this rare disease.

AB - Follicular dendritic cell sarcomas (FDCS) are grouped with the histiocytic and dendritic cell neoplasms. The natural history and response to different treatments have not been well established. The cases of 14 patients with FDCS who were seen at M. D. Anderson between 1995 and 2005 were reviewed. Median patient age was 48 years (range, 25-69 years). Histologically, four cases showed low-grade features, three cases showed low-grade features with focal high-grade features, and five cases showed high-grade features. Tumors were positive for CD21, CD23, and CD35 in 83, 90, and 44% of cases, respectively. Twelve (92%) of 13 tumors were strongly positive for epidermal growth factor receptor. Information on initial treatment was available in 11 patients, which included surgery alone in one patient, surgery and radiation in two, surgery and chemotherapy in one, chemotherapy alone in three, chemotherapy and radiation in one, surgery followed by radiation and chemotherapy in three patients. In eight patients the initial chemotherapy regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone. Complete remission was achieved in 7 (63%) of 11 patients. Ten patients were alive at a median follow up of 22 months, 3 (23%) of 13 had no evidence of disease, and 7 (53%) of 13 patients were alive with disease. Follicular sarcoma is an aggressive neoplasm. Although most of the patients initially responded to treatment, the majority of them (81%) relapsed. A better understanding of the biology of FDCS could guide our efforts in the development of new treatment modalities for this rare disease.

UR - http://www.scopus.com/inward/record.url?scp=34547699189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547699189&partnerID=8YFLogxK

U2 - 10.1002/ajh.20852

DO - 10.1002/ajh.20852

M3 - Article

VL - 82

SP - 725

EP - 728

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 8

ER -